Search results for: 'simulation show how engines work'

11 Nov 2022  |  North America  |  Market Research

Global Contract Research Organization (CRO) Growth Opportunities

Strong Competitive Intensity is Mandating a Greater Industry Convergence Resulting in a Strong Market Growth

Infographics

×

Key Issues Addressed

The COVID-19 pandemic led to a sudden surge in R&D activities across the world. Both small and large pharmaceutical and biotech companies were engaged in tremendous efforts to either develop new molecules or repurpose existing therapies as potential drugs for COVID-19 treatment. The trend is likely to continue with small-to-medium-segment and e...

12 Aug 2020  |  North America  |  Market Research

New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025

AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities

Infographics

×

Key Issues Addressed

Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...

27 Nov 2019  |  North America  |  Market Research

Global Contract Research Organization (CRO) Market, Forecast to 2024

Increased Technology Adoption in the Form of eClinical Solutions and Innovative Trial Designs is Expected to Transform the CRO Landscape

Infographics

×

Key Issues Addressed

Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape. Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025. In coordination with the indust...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

08 Mar 2022  |  North America  |  Market Outlook

Global Pharmaceuticals Outlook, 2022

The Digitalization of the Pharmaceuticals Value Chain is Opening up New Growth Opportunities for Stakeholders

Infographics

×

Key Issues Addressed

Frost & Sullivan offers an outlook for the global pharmaceuticals market for 2022-2026, including emerging trends and growth opportunities. Prioritizing booster doses over initial dose coverage is negatively impacting the global mitigation of the COVID-19 pandemic, which is resulting in severe implications on health and social and economic well-bei...

The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Indu...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

As one lives longer, one needs to increasingly battle age-related disorders. Neurodegenerative disorders are the most worrisome, because they impact millions of people around the world and lack any curative therapy. While companies continue their search, they are also battling declining revenues from marketed products used to manage symptoms. Heavy...